Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Early stopping rules in oncology: considerations for clinicians.

Mukherjee SD, Goffin JR, Taylor V, Anderson KK, Pond GR.

Eur J Cancer. 2011 Nov;47(16):2381-6. doi: 10.1016/j.ejca.2011.05.019. Epub 2011 Jun 16. Review.

PMID:
21684153
2.

Data monitoring committees, interim analysis and early termination in paediatric trials.

Fernandes RM, van der Lee JH, Offringa M.

Acta Paediatr. 2011 Oct;100(10):1386-92. doi: 10.1111/j.1651-2227.2011.02282.x. Epub 2011 Apr 8.

PMID:
21434998
3.

Early stopping rules--clinical perspectives and ethical considerations.

Baum M, Houghton J, Abrams K.

Stat Med. 1994 Jul 15-30;13(13-14):1459-69; discussion 1471-2.

PMID:
7973225
4.

Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.

Ball G, Piller LB, Silverman MH.

Contemp Clin Trials. 2011 Sep;32 Suppl 1:S2-4. doi: 10.1016/j.cct.2011.05.010. Epub 2011 Jun 6.

PMID:
21664987
5.

Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation.

Booth CM, Ohorodnyk P, Zhu L, Tu D, Meyer RM.

Eur J Cancer. 2011 Apr;47(6):854-63. doi: 10.1016/j.ejca.2010.12.005. Epub 2011 Feb 4. Review.

PMID:
21296570
6.

Stopping at nothing? Some dilemmas of data monitoring in clinical trials.

Goodman SN.

Ann Intern Med. 2007 Jun 19;146(12):882-7.

PMID:
17577008
7.

An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.

Stegert M, Kasenda B, von Elm E, You JJ, Bl├╝mle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Briel M; DISCO study group.

J Clin Epidemiol. 2016 Jan;69:152-60. doi: 10.1016/j.jclinepi.2015.05.023. Epub 2015 Jun 4. Review.

PMID:
26361993
8.

Current controversies in data monitoring for clinical trials.

Pocock SJ.

Clin Trials. 2006;3(6):513-21.

PMID:
17170035
9.

Stopping rules, interim analyses and data monitoring committees.

Ashby D, Machin D.

Br J Cancer. 1993 Dec;68(6):1047-50. No abstract available.

10.

Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerations.

Ball G, Piller LB.

Contemp Clin Trials. 2011 Sep;32 Suppl 1:S5-7. doi: 10.1016/j.cct.2011.05.009. Epub 2011 Jun 6.

PMID:
21664986
11.

Data monitoring committees and interim monitoring guidelines.

Freidlin B, Korn EL, George SL.

Control Clin Trials. 1999 Oct;20(5):395-407. Review.

PMID:
10503800
12.

The dangers of stopping a trial too early.

Briel M, Bassler D, Wang AT, Guyatt GH, Montori VM.

J Bone Joint Surg Am. 2012 Jul 18;94 Suppl 1:56-60. doi: 10.2106/JBJS.K.01412.

PMID:
22810449
13.

Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.

Crowley J, Green S, Liu PY, Wolf M.

Stat Med. 1994 Jul 15-30;13(13-14):1391-9.

PMID:
7973218
14.

Role of the Data and Safety Monitoring Committee (DSMC).

Wilhelmsen L.

Stat Med. 2002 Oct 15;21(19):2823-9.

PMID:
12325098
15.

Interpretation of Clinical Trials That Stopped Early.

Viele K, McGlothlin A, Broglio K.

JAMA. 2016 Apr 19;315(15):1646-7. doi: 10.1001/jama.2016.2628. No abstract available.

PMID:
27092832
16.

Interim analysis in randomized trials: DAMOCLES' sword?

Besselink MG, van der Graaf Y, Gooszen HG.

J Clin Epidemiol. 2010 Apr;63(4):353-4. doi: 10.1016/j.jclinepi.2009.07.004. Epub 2009 Dec 2. No abstract available.

PMID:
19959333
17.

Issues in data monitoring and interim analysis of trials.

Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA; DAMOCLES study group.

Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv. Review.

18.

Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial.

Gilpin AM, Holbrook JT, Jabs DA, Meinert CL; Studies of Ocular Complications of AIDS Research Group.

Control Clin Trials. 2003 Feb;24(1):92-8.

PMID:
12559647
19.

Stopping guidelines for an effectiveness trial: what should the protocol specify?

Tyson JE, Pedroza C, Wallace D, D'Angio C, Bell EF, Das A.

Trials. 2016 May 10;17(1):240. doi: 10.1186/s13063-016-1367-4.

20.

Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.

Perrem LM, Gosling S, Ravikumar I, Khashan AS, Miletin J, Ryan CA, Dempsey E.

Acta Paediatr. 2017 Jan;106(1):30-33. doi: 10.1111/apa.13593. Epub 2016 Oct 25.

PMID:
27637413

Supplemental Content

Support Center